Induced Pluripotent Stem Cells Market Size to Hit USD 5.12 Billion by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Induced Pluripotent Stem Cells Market

5.1. COVID-19 Landscape: Induced Pluripotent Stem Cells Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Induced Pluripotent Stem Cells Market, By Application

8.1. Induced Pluripotent Stem Cells Market Revenue and Volume, by Application

8.1.1. Drug Discovery & Toxicology Testing

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Disease Modeling

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Regenerative Medicine

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Stem Cell Banking

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Academic Research

8.1.5.1. Market Revenue and Volume Forecast

8.1.6. Gene Editing Research (iPSC + CRISPR/Cas9)

8.1.6.1. Market Revenue and Volume Forecast

Chapter 9. Global Induced Pluripotent Stem Cells Market, By Cell Type / Lineage

9.1. Induced Pluripotent Stem Cells Market Revenue and Volume, by Cell Type / Lineage

9.1.1. Hematopoietic Cells

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Cardiomyocytes

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Neural Stem Cells

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Hepatocytes

9.1.4.1. Market Revenue and Volume Forecast

9.1.5. Retinal Pigment Epithelium (RPE)

9.1.5.1. Market Revenue and Volume Forecast

9.1.6. Pancreatic Beta Cells

9.1.6.1. Market Revenue and Volume Forecast

9.1.7. Chondrocytes & Osteoblasts

9.1.7.1. Market Revenue and Volume Forecast

9.1.8. Others (T cells, epithelial cells, etc.)

9.1.8.1. Market Revenue and Volume Forecast

Chapter 10. Global Induced Pluripotent Stem Cells Market, By Product & Service

10.1. Induced Pluripotent Stem Cells Market Revenue and Volume, by Product & Service

10.1.1. iPSC-Derived Cells

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. iPSC Reprogramming Kits & Culture Media

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. iPSC Lines & Custom Cell Engineering Services

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. CRISPR & Genetic Modification Tools

10.1.4.1. Market Revenue and Volume Forecast

10.1.5. Stem Cell Banking Services

10.1.5.1. Market Revenue and Volume Forecast

10.1.6. Assay Kits for Differentiation, QC, and Validation

10.1.6.1. Market Revenue and Volume Forecast

10.1.7. Instruments & Bioreactors

10.1.7.1. Market Revenue and Volume Forecast

Chapter 11. Global Induced Pluripotent Stem Cells Market, By End User

11.1. Induced Pluripotent Stem Cells Market Revenue and Volume, by End User

11.1.1. Pharmaceutical & Biotech Companies

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Academic & Research Institutions

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. CROs & CDMOs

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Cell Therapy Companies

11.1.4.1. Market Revenue and Volume Forecast

11.1.5. Government & Non-Profit Organizations

11.1.5.1. Market Revenue and Volume Forecast

Chapter 12. Global Induced Pluripotent Stem Cells Market, By Technology

12.1. Induced Pluripotent Stem Cells Market Revenue and Volume, by Technology

12.1.1. Integrating Vectors (e.g., Retroviruses)

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Non-Integrating Methods

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Sendai virus

12.1.3.1. Market Revenue and Volume Forecast

12.1.4. Episomal vectors

12.1.4.1. Market Revenue and Volume Forecast

12.1.5. mRNA & Protein-based reprogramming

12.1.5.1. Market Revenue and Volume Forecast

12.1.6. CRISPR-Cas9 & Gene Editing

12.1.6.1. Market Revenue and Volume Forecast

12.1.7. Automated iPSC Production Platformm

12.1.7.1. Market Revenue and Volume Forecast

Chapter 13. Global Induced Pluripotent Stem Cells Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Application

13.1.2. Market Revenue and Volume Forecast, by Cell Type / Lineage

13.1.3. Market Revenue and Volume Forecast, by Product & Service

13.1.4. Market Revenue and Volume Forecast, by End User

13.1.5. Market Revenue and Volume Forecast, by Technology

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Application

13.1.6.2. Market Revenue and Volume Forecast, by Cell Type / Lineage

13.1.6.3. Market Revenue and Volume Forecast, by Product & Service

13.1.6.4. Market Revenue and Volume Forecast, by End User

13.1.6.5. Market Revenue and Volume Forecast, by Technology

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Application

13.1.7.2. Market Revenue and Volume Forecast, by Cell Type / Lineage

13.1.7.3. Market Revenue and Volume Forecast, by Product & Service

13.1.7.4. Market Revenue and Volume Forecast, by End User

13.1.7.5. Market Revenue and Volume Forecast, by Technology

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Application

13.2.2. Market Revenue and Volume Forecast, by Cell Type / Lineage

13.2.3. Market Revenue and Volume Forecast, by Product & Service

13.2.4. Market Revenue and Volume Forecast, by End User

13.2.5. Market Revenue and Volume Forecast, by Technology

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Application

13.2.6.2. Market Revenue and Volume Forecast, by Cell Type / Lineage

13.2.6.3. Market Revenue and Volume Forecast, by Product & Service

13.2.7. Market Revenue and Volume Forecast, by End User

13.2.8. Market Revenue and Volume Forecast, by Technology

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Application

13.2.9.2. Market Revenue and Volume Forecast, by Cell Type / Lineage

13.2.9.3. Market Revenue and Volume Forecast, by Product & Service

13.2.10. Market Revenue and Volume Forecast, by End User

13.2.11. Market Revenue and Volume Forecast, by Technology

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Application

13.2.12.2. Market Revenue and Volume Forecast, by Cell Type / Lineage

13.2.12.3. Market Revenue and Volume Forecast, by Product & Service

13.2.12.4. Market Revenue and Volume Forecast, by End User

13.2.13. Market Revenue and Volume Forecast, by Technology

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Application

13.2.14.2. Market Revenue and Volume Forecast, by Cell Type / Lineage

13.2.14.3. Market Revenue and Volume Forecast, by Product & Service

13.2.14.4. Market Revenue and Volume Forecast, by End User

13.2.15. Market Revenue and Volume Forecast, by Technology

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Application

13.3.2. Market Revenue and Volume Forecast, by Cell Type / Lineage

13.3.3. Market Revenue and Volume Forecast, by Product & Service

13.3.4. Market Revenue and Volume Forecast, by End User

13.3.5. Market Revenue and Volume Forecast, by Technology

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Application

13.3.6.2. Market Revenue and Volume Forecast, by Cell Type / Lineage

13.3.6.3. Market Revenue and Volume Forecast, by Product & Service

13.3.6.4. Market Revenue and Volume Forecast, by End User

13.3.7. Market Revenue and Volume Forecast, by Technology

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Application

13.3.8.2. Market Revenue and Volume Forecast, by Cell Type / Lineage

13.3.8.3. Market Revenue and Volume Forecast, by Product & Service

13.3.8.4. Market Revenue and Volume Forecast, by End User

13.3.9. Market Revenue and Volume Forecast, by Technology

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Application

13.3.10.2. Market Revenue and Volume Forecast, by Cell Type / Lineage

13.3.10.3. Market Revenue and Volume Forecast, by Product & Service

13.3.10.4. Market Revenue and Volume Forecast, by End User

13.3.10.5. Market Revenue and Volume Forecast, by Technology

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Application

13.3.11.2. Market Revenue and Volume Forecast, by Cell Type / Lineage

13.3.11.3. Market Revenue and Volume Forecast, by Product & Service

13.3.11.4. Market Revenue and Volume Forecast, by End User

13.3.11.5. Market Revenue and Volume Forecast, by Technology

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Application

13.4.2. Market Revenue and Volume Forecast, by Cell Type / Lineage

13.4.3. Market Revenue and Volume Forecast, by Product & Service

13.4.4. Market Revenue and Volume Forecast, by End User

13.4.5. Market Revenue and Volume Forecast, by Technology

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Application

13.4.6.2. Market Revenue and Volume Forecast, by Cell Type / Lineage

13.4.6.3. Market Revenue and Volume Forecast, by Product & Service

13.4.6.4. Market Revenue and Volume Forecast, by End User

13.4.7. Market Revenue and Volume Forecast, by Technology

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Application

13.4.8.2. Market Revenue and Volume Forecast, by Cell Type / Lineage

13.4.8.3. Market Revenue and Volume Forecast, by Product & Service

13.4.8.4. Market Revenue and Volume Forecast, by End User

13.4.9. Market Revenue and Volume Forecast, by Technology

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Application

13.4.10.2. Market Revenue and Volume Forecast, by Cell Type / Lineage

13.4.10.3. Market Revenue and Volume Forecast, by Product & Service

13.4.10.4. Market Revenue and Volume Forecast, by End User

13.4.10.5. Market Revenue and Volume Forecast, by Technology

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Application

13.4.11.2. Market Revenue and Volume Forecast, by Cell Type / Lineage

13.4.11.3. Market Revenue and Volume Forecast, by Product & Service

13.4.11.4. Market Revenue and Volume Forecast, by End User

13.4.11.5. Market Revenue and Volume Forecast, by Technology

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Application

13.5.2. Market Revenue and Volume Forecast, by Cell Type / Lineage

13.5.3. Market Revenue and Volume Forecast, by Product & Service

13.5.4. Market Revenue and Volume Forecast, by End User

13.5.5. Market Revenue and Volume Forecast, by Technology

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Application

13.5.6.2. Market Revenue and Volume Forecast, by Cell Type / Lineage

13.5.6.3. Market Revenue and Volume Forecast, by Product & Service

13.5.6.4. Market Revenue and Volume Forecast, by End User

13.5.7. Market Revenue and Volume Forecast, by Technology

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Application

13.5.8.2. Market Revenue and Volume Forecast, by Cell Type / Lineage

13.5.8.3. Market Revenue and Volume Forecast, by Product & Service

13.5.8.4. Market Revenue and Volume Forecast, by End User

13.5.8.5. Market Revenue and Volume Forecast, by Technology

Chapter 14. Company Profiles

14.1. BlueRock Therapeutics (Bayer)

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Cellular Dynamics International (Fujifilm Group)

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Century Therapeutics

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Evotec SE

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Lonza Group AG

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Ncardia

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Newcells Biotech

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Pluricell Biotech

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. REPROCELL Inc.

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Sumitomo Pharma Co., Ltd.

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The induced pluripotent stem cells market size is expected to increase from USD 1.93 billion in 2024 to USD 5.12 billion by 2034.

The induced pluripotent stem cells market is expected to grow at a compound annual growth rate (CAGR) of around 10.25% from 2025 to 2034.

The major players in the induced pluripotent stem cells market include Allele Biotechnology & Pharmaceuticals, Axol Bioscience Ltd., bit.bio, BlueRock Therapeutics (Bayer), BrainXell, Inc., Cellular Dynamics International (Fujifilm Group), Century Therapeutics, Corning Incorporated, Evotec SE, Fujifilm Cellular Dynamics, Inc., Lifeline Cell Technology, Lonza Group AG, Ncardia, Newcells Biotech, Pluricell Biotech, REPROCELL Inc., Stemcell Technologies Inc., Sumitomo Pharma Co., Ltd., Takara Bio Inc., and Thermo Fisher Scientific, Inc.

The driving factors of the induced pluripotent stem cells market are the growing preference for physiologically relevant models is fuelling the adoption of iPSC-derived 3D organoids in preclinical research.

North America region will lead the global induced pluripotent stem cells market during the forecast period 2025 to 2034.